title: Effects of the somatostatin analogue SMS 201-995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man.
abstract: 1. Somatostatin analogues, such as SMS 201-995 (sandostatin), have been suggested as treatment for a variety of disease states including acromegaly, secretory gastrointestinal tumours and diabetes mellitus. 2. Somatostatin-14 has actions to prolong gastro-intestinal transit time and inhibit intestinal absorption, and we have therefore studied the effects of SMS 201-995 on these processes. Five male subjects received a test meal having been given either saline or 50 micrograms of SMS 201-995 subcutaneously 30 min before ingestion. 3. SMS 201-995 caused a delay in mouth-to-caecum transit time for lactulose assessed by breath hydrogen analysis (316 +/- 17 vs 192 +/- 14 min, mean +/- SEM, P less than 0.01), a delay (234 vs 120 min, P less than 0.05) in the plasma peak of the non-metabolizable glucose analogue 3-O-methylglucose and conversion of the expected postprandial rise in serum triglycerides (with saline 1.02 +/- 0.20 to 1.51 +/- 0.28 mmol/l, P less than 0.05) to a decrease below basal values (with SMS 201-995 0.97 +/- 0.80 to 0.79 +/- 0.11 mmol/l, P less than 0.05). 4. After SMS 201-995, an enhancement of the increase in blood glucose (8.2 +/- 0.7 vs 4.7 +/- 0.2 mmol/l, P less than 0.01) and inhibition and postponement of the postprandial rise in insulin (27.6 +/- 6.7 vs 9.9 +/- 2.1 m-units/l, P less than 0.05) occurred. Furthermore, a rise in non-esterified fatty acids, glycerol and 3-hydroxybutyrate, compared with the decline in concentrations of these metabolites after saline, was observed.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, U.K.
authors.forename: N
authors.initials: N
authors.lastname: Møller
authors.forename: G
authors.initials: G
authors.lastname: Petrany
authors.forename: D
authors.initials: D
authors.lastname: Cassidy
authors.forename: W L
authors.initials: WL
authors.lastname: Sheldon
authors.forename: D G
authors.initials: DG
authors.lastname: Johnston
authors.forename: M F
authors.initials: MF
authors.lastname: Laker
mesh_terms: D020155:3-Hydroxybutyric Acid; D019325:3-O-Methylglucose; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001944:Breath Tests; D004040:Dietary Carbohydrates / Q000378:metabolism; D004041:Dietary Fats / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005772:Gastrointestinal Transit / Q000187:drug effects*; D005990:Glycerol / Q000097:blood; D006801:Humans; D006885:Hydroxybutyrates / Q000097:blood; D007328:Insulin / Q000097:blood; D007408:Intestinal Absorption / Q000187:drug effects*; D007792:Lactulose / Q000378:metabolism; D008297:Male; D008757:Methylglucosides / Q000378:metabolism; D015282:Octreotide / Q000494:pharmacology*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007328:Insulin; D008757:Methylglucosides; D014280:Triglycerides; D019325:3-O-Methylglucose; D007792:Lactulose; D005990:Glycerol; D015282:Octreotide; D020155:3-Hydroxybutyric Acid